Evaluation of multiple biomarkers to estimate risk of cancer in gynecology patients
presenting with a pelvic mass
Research Question:
Can the technology, ParsortixTM PC1 system, help physicians determine whether
an abnormal pelvic mass in women is benign (non-cancerous) or malignant (cancerous)
using a blood test?
Basic Study Information
Purpose:
The purpose of this study is to validate and refine a technology that can help physicians
determine whether
an abnormal pelvic mass in women is benign (non-cancerous) or malignant (cancerous)
using a blood test.
The specific technology is called ParsortixTM PC1 system, a semi-automated system
capable of capturing and
harvesting rare cells for subsequent analysis from blood based on the size and deformability
of the cells.
Location: University of Rochester Medical Center
Study Reference #: IGYN18142
Lead Researcher (Principal Investigator)
Lead Researcher:
Richard Moore
Study Contact Information
Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@URMC.Rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search